Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Stryker's Trevo, First Retriever Indicated To Treat Acute Stroke Within 24 Hours, Earns CE Mark

Executive Summary

Stryker announced CE-mark approval of expanded labeling for its Trevo Retriever to reflect the results of the DAWN and DEFUSE 3 trials, which show that treatment of acute ischemic stroke with Trevo and standard medical therapy up to 24 hours after symptom-onset improves 90-day outcomes better than medical therapy alone. Previously, six hours was considered the maximum time from symptom onset during which this type of intervention could be effective.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

MT122621

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel